Thompson Rubinstein Investment Management Inc. OR trimmed its position in shares of Stryker Corporation (NYSE:SYK) by 1.3% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 29,504 shares of the medical technology company’s stock after selling 400 shares during the quarter. Stryker makes up approximately 1.5% of Thompson Rubinstein Investment Management Inc. OR’s holdings, making the stock its 26th largest position. Thompson Rubinstein Investment Management Inc. OR’s holdings in Stryker were worth $4,568,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently bought and sold shares of the business. Coldstream Capital Management Inc. boosted its position in shares of Stryker by 3.7% in the 2nd quarter. Coldstream Capital Management Inc. now owns 17,445 shares of the medical technology company’s stock worth $2,421,000 after purchasing an additional 626 shares in the last quarter. Retirement Systems of Alabama boosted its position in shares of Stryker by 2.5% in the 3rd quarter. Retirement Systems of Alabama now owns 234,870 shares of the medical technology company’s stock worth $33,356,000 after purchasing an additional 5,656 shares in the last quarter. Toronto Dominion Bank boosted its position in shares of Stryker by 25.8% in the 2nd quarter. Toronto Dominion Bank now owns 105,403 shares of the medical technology company’s stock worth $14,625,000 after purchasing an additional 21,585 shares in the last quarter. Colonial Trust Advisors boosted its position in shares of Stryker by 56.1% in the 2nd quarter. Colonial Trust Advisors now owns 23,446 shares of the medical technology company’s stock worth $3,254,000 after purchasing an additional 8,426 shares in the last quarter. Finally, Cornerstone Capital Management Holdings LLC. boosted its position in shares of Stryker by 3.1% in the 3rd quarter. Cornerstone Capital Management Holdings LLC. now owns 55,255 shares of the medical technology company’s stock worth $7,847,000 after purchasing an additional 1,683 shares in the last quarter. 74.88% of the stock is currently owned by institutional investors and hedge funds.

A number of analysts have recently commented on the company. Needham & Company LLC reissued a “hold” rating on shares of Stryker in a research report on Wednesday. Royal Bank of Canada reissued a “buy” rating and issued a $175.00 price target on shares of Stryker in a research report on Tuesday, January 9th. Piper Jaffray Companies boosted their price target on Stryker from $156.00 to $166.00 and gave the stock an “overweight” rating in a research report on Tuesday, January 9th. Cantor Fitzgerald reissued a “neutral” rating and issued a $163.00 price target on shares of Stryker in a research report on Friday, January 5th. Finally, Wells Fargo & Co reissued an “outperform” rating and issued a $174.00 price target (up from $166.00) on shares of Stryker in a research report on Tuesday, January 2nd. They noted that the move was a valuation call. Two analysts have rated the stock with a sell rating, nine have assigned a hold rating and thirteen have given a buy rating to the company. The company has a consensus rating of “Hold” and an average target price of $156.60.

Stryker Corporation (NYSE:SYK) traded up $0.61 during mid-day trading on Wednesday, reaching $160.08. The company had a trading volume of 644,487 shares, compared to its average volume of 1,223,500. The company has a market cap of $59,800.00, a PE ratio of 34.13, a PEG ratio of 2.27 and a beta of 0.78. Stryker Corporation has a fifty-two week low of $119.17 and a fifty-two week high of $164.20. The company has a debt-to-equity ratio of 0.63, a current ratio of 2.37 and a quick ratio of 1.61.

Stryker (NYSE:SYK) last released its quarterly earnings data on Thursday, October 26th. The medical technology company reported $1.52 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.50 by $0.02. The business had revenue of $3.01 billion for the quarter, compared to analysts’ expectations of $2.97 billion. Stryker had a return on equity of 24.11% and a net margin of 14.67%. The firm’s quarterly revenue was up 6.1% on a year-over-year basis. During the same period in the prior year, the firm posted $1.39 EPS. analysts predict that Stryker Corporation will post 6.49 EPS for the current year.

The business also recently announced a quarterly dividend, which will be paid on Wednesday, January 31st. Shareholders of record on Friday, December 29th will be paid a dividend of $0.47 per share. The ex-dividend date is Thursday, December 28th. This is a positive change from Stryker’s previous quarterly dividend of $0.43. This represents a $1.88 dividend on an annualized basis and a yield of 1.17%. Stryker’s payout ratio is currently 40.09%.

In other Stryker news, insider Lonny J. Carpenter sold 5,000 shares of the business’s stock in a transaction on Friday, November 3rd. The shares were sold at an average price of $155.34, for a total transaction of $776,700.00. Following the completion of the sale, the insider now directly owns 83,207 shares in the company, valued at approximately $12,925,375.38. The sale was disclosed in a document filed with the SEC, which is available through this link. 7.40% of the stock is currently owned by insiders.

ILLEGAL ACTIVITY WARNING: “Thompson Rubinstein Investment Management Inc. OR Cuts Holdings in Stryker Corporation (SYK)” was published by Watch List News and is owned by of Watch List News. If you are viewing this piece on another website, it was copied illegally and republished in violation of United States and international trademark & copyright law. The original version of this piece can be accessed at https://www.watchlistnews.com/thompson-rubinstein-investment-management-inc-or-cuts-holdings-in-stryker-corporation-syk/1810973.html.

Stryker Profile

Stryker Corporation is a medical technology company. The Company offers a range of medical technologies, including orthopedic, medical and surgical, and neurotechnology and spine products. The Company’s segments include Orthopaedics; MedSurg; Neurotechnology and Spine, and Corporate and Other. The Orthopaedics segment includes reconstructive (hip and knee) and trauma implant systems and other related products.

Institutional Ownership by Quarter for Stryker (NYSE:SYK)

Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with Analyst Ratings Network's FREE daily email newsletter.